DE000UL3RBH1/ DE000UL3RBH1 /
2024-06-17 7:31:05 PM | Chg.+0.060 | Bid9:07:20 AM | Ask9:07:20 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.840EUR | +7.69% | 0.880 Bid Size: 25,000 |
0.890 Ask Size: 25,000 |
MERCK KGAA O.N. | 179.6135 - | 2078-12-31 | Put |
GlobeNewswire
9:00 AM
Precision-Panc Team Open the PRIMUS-006 Study, a Novel Combination of IMM-101, Gemcitabine and Pembr...
GlobeNewswire
06-17
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Design...
GlobeNewswire
06-03
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
05-29
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA